Skip to main content

Your Source for Up-to-Date Pharma and Medical Device News

Join thousands of industry leaders who receive the NSF pharma biotech or medical device/IVD newsletters each month.

The NSF pharmaceutical and medical device/IVD newsletters are trusted by thousands of industry leaders who rely on us for clarity in a rapidly evolving global regulatory landscape.

Each month, we deliver expert insights and practical updates on topics such as:

  • Compliance and resilience
  • Remediation strategies
  • QMSR readiness
  • Complaint handling best practises
  • Auditing and inspection preparedness
  • Post-market surveillance
  • Emerging AI standards in life sciences
  • Clinical trial considerations
  • Industry training opportunities.

Stay informed of the latest developments that matter.

Sign up below to receive our monthly newsletters.

Subscribe to our monthly newsletters

Complete your details below to receive the newsletter.

How NSF Can Help You

Get in touch to find out how we can help you and your business thrive.

What’s New with NSF

  • NSF Issues First-Ever MSC Certification for an Eel Fishery to Perupez S.A.C. and Sakana del Peru

    June 19, 2026
    Third-party certification plays a key role in independently verifying the sustainability of seafood operations.
    Read the Story
  • NSF Ends UK’s Three-Year Testing Gap with REG 31 Testing Designation

    May 20, 2026
    NSF’s Oakdale laboratory becomes the UK’s sole facility offering comprehensive BS 6920 and REG 31 testing, closing a critical drinking water safety gap.
    Read the Story
  • NSF Annual Review and Impact Report 2025 Now Live

    April 20, 2026
    NSF has published its Annual Review and Impact Report 2025, detailing the organization’s progress over the past year and outlining strategic priorities for 2026.
    Read the Story
  • Visit NSF at Making Pharma 2026

    April 10, 2026
    Connect with our experts to discover how we help leading pharmaceutical and biotechnology companies achieve regulatory compliance and operational excellence.
    Read the Story